Deschatelets Pascal's Form 4 filing
Apellis Pharmaceuticals, Inc.APLS · filed May 9, 2024
- Accession no.
- 0001127602-24-014811
- Filed
- May 9, 2024
- Trade date
- May 8, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.34M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deschatelets PascalCIK 0001657720 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2024 | Common Stock | MOption exerciseAcquired | +78,907 | $4.31 | +$340,089.17 | 1,194,890 | Direct | |
| May 8, 2024 | Common Stock | SSaleDisposed | −56,335 | $42.15F2 | −$2,374,520.25 | 1,138,555 | Direct | |
| May 8, 2024 | Common Stock | SSaleDisposed | −22,472 | $42.85F3 | −$962,925.2 | 1,116,083 | Direct | |
| May 8, 2024 | Common Stock | SSaleDisposed | −100 | $44.03 | −$4,403 | 1,115,983 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2024 | Common Stock | MOption exerciseDisposed | −78,907 | $0.00 | $0 | 108,622 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $41.575 - $42.570. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $42.575 - $43.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.